Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of ubenimex.
1. A method of treating non-alcoholic steatohepatitis (NASH), the method comprising administering to a subject in need of treatment a therapeutically effective amount of ubenimex.
2. The method of claim 1 , wherein the subject has early-stage or middle-stage NASH.
3. The method of claim 1 , wherein the ubenimex is administered at a total daily dose in the range of 5 mg to 1000 mg.
4. The method of claim 1 , wherein the ubenimex is administered at a daily dose of about 5 mg to about 450 mg.
5. The method of claim 1 , wherein the ubenimex is administered for at least 4 weeks.
6. The method of claim 5 , wherein the ubenimex is administered for at least 12 weeks.
7. The method of claim 1 , wherein treatment results in a reduction in plasma CK-18 levels in the subject.
8. The method of claim 1 , wherein treatment results in a reduction in hepatocyte ballooning in the subject.
9. The method of claim 1 , wherein the ubenimex is administered in combination with a second therapeutic agent.
10. The method of claim 9 , wherein the second therapeutic agent is a farnesoid X receptor (FXR) agonist, a peroxisome proliferator-activator receptor (PPAR) agonist, aramchol, a caspase inhibitor, a galectin 3 inhibitor, a mitogen-activated protein kinase 5 (MAPK5) inhibitor, a fibroblast growth factor 19 (FGF19) agonist, a FGF21 agonist, a leukotriene D4 (LTD4) receptor antagonist, a niacin analog, an apical sodium bile acid cotransporter (ASBT) inhibitor, an apoptosis signal regulating kinase 1 (ASK1) inhibitor, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin receptor blocker, a chemokine receptor inhibitor, a thiozolidinedione, a GLP-1 analog, a biguanide, or a non-steroidal anti-inflammatory drug (NSAID).
11. A method of delaying or preventing the progression of non-alcoholic fatty liver disease (NAFLD) to NASH in a subject having NAFLD, the method comprising administering to the subject a therapeutically effective amount of ubenimex.
12. The method of claim 11 , wherein treatment results in a reduction in hepatocyte ballooning in the subject.
13. The method of claim 11 , wherein the ubenimex is administered at a daily dose in the range of 5 mg to 1000 mg.
14. The method of claim 11 , wherein the ubenimex is administered at a daily dose of about 5 mg to about 450 mg.
15. The method of claim 11 , wherein the ubenimex is administered for at least 4 weeks.
16. The method of claim 15 , wherein the ubenimex is administered for at least 12 weeks.
17. A method of decreasing inflammation and/or fibrosis in a subject having NASH, the method comprising administering to the subject a therapeutically effective amount of ubenimex for at least 24 weeks.
18. The method of claim 17 , wherein the ubenimex is administered for at least 48 weeks.
19. The method of claim 11 , wherein the ubenimex is administered in combination with a second therapeutic agent.
20. The method of claim 19 , wherein the second therapeutic agent is a FXR agonist, a PPAR agonist, aramchol, a caspase inhibitor, a galectin 3 inhibitor, a MAPK5 inhibitor, a FGF19 agonist, a FGF21 agonist, a LTD4 receptor antagonist, a niacin analog, an ASBT inhibitor, an ASK1 inhibitor, an ACE inhibitor, an angiotensin receptor blocker, a chemokine receptor inhibitor, a thiozolidinedione, a GLP-1 analog, a biguanide, or an NSAID.